← Back to Search

Unknown

GLS-1027 for COVID-19

Phase 2
Waitlist Available
Research Sponsored by GeneOne Life Science, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 28 days
Awards & highlights

Study Summary

This trialtests a drug to prevent lung damage from severe cases of COVID-19.

Eligible Conditions
  • Pneumonitis
  • Coronavirus

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~28 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and 28 days for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Incidence of serious adverse events relative to treatment group
Incidence of treatment failure at day 28 from enrollment
Secondary outcome measures
Assess the maximal level of Positive End-Expiratory Pressure (PEEP) for subjects who are intubated relative to treatment group.
Assess the number of days of NIV, high-flow O2, or mechanical ventilation relative to treatment
Assess the number of days of PEEP > 5 cm H2O for subjects who are intubated relative to treatment group
+3 more

Trial Design

3Treatment groups
Experimental Treatment
Placebo Group
Group I: GLS-1027 360 mgExperimental Treatment1 Intervention
Three 120 mg pills of GLS-1027 given by mouth once daily
Group II: GLS-1027 120 mgExperimental Treatment1 Intervention
One 120 mg pill of GLS-1027 + 2 Placebo pills given by mouth once daily
Group III: PlaceboPlacebo Group1 Intervention
Three Placebo pills given by mouth once daily

Find a Location

Who is running the clinical trial?

GeneOne Life Science, Inc.Lead Sponsor
15 Previous Clinical Trials
1,308 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
GLS-1027 for the Prevention of Severe Pneumonitis Caused by SARS-CoV-2 Infection (COVID-19)
2021. "GLS-1027 for the Prevention of Severe Pneumonitis Caused by SARS-CoV-2 Infection (COVID-19)". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04590547.
All > Covid 19
~34 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top